Anti-Ovastacin Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibody targeting ovastacin (ASTL), the oocyte-specific metalloproteinase responsible for ZP2 cleavage and polyspermy block after fertilization.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-Mouse, Rat, Pan, Dog
UniProt
Q6HA08
Size
100ug
Cat. #
RP2Ovastacin

In stock

SKU
RP-Ovastacin

Options

As low as: $130.00

Target Overview

Ovastacin (astacin-like metalloendopeptidase, ASTL; UniProt Q6HA08) is an oocyte-specific metalloproteinase that serves as a critical oolemmal receptor in mammalian fertilization. This 431-residue enzyme belongs to the astacin family of zinc-dependent metalloproteases and functions as the primary ZP2-proteinase responsible for post-fertilization modification of the zona pellucida. Following sperm-egg fusion and cortical granule exocytosis, ovastacin is released from cortical granules and cleaves ZP2, one of the major structural glycoproteins of the zona pellucida that mediates sperm binding. This proteolytic modification renders the zona pellucida refractory to additional sperm binding, thereby preventing polyspermy. Ovastacin is expressed exclusively in oocytes and localizes to the cytoplasm prior to fertilization. Loss-of-function mutations in ASTL have been associated with female infertility characterized by abnormal fertilization and developmental arrest, underscoring its essential role in human reproduction.

Background

Ovastacin represents a unique member of the astacin metalloproteinase superfamily, distinguished by its highly restricted expression pattern and specialized function in reproductive biology. The protein mediates the zona pellucida hardening reaction—also known as the slow block to polyspermy—which permanently modifies the zona pellucida structure within minutes after fertilization. This process differs from the rapid electrical block and is essential for monospermic fertilization in mammals. The substrate specificity of ovastacin for ZP2 is remarkable: it cleaves the N-terminal region of ZP2, destroying the sperm receptor function while preserving the structural integrity of the zona pellucida matrix. Recent genetic studies have identified homozygous variants in ASTL as causative factors in human female infertility. Xie et al. (2025) reported novel homozygous ASTL variants in patients presenting with abnormal fertilization patterns, providing direct clinical evidence for ovastacin's essential role in human reproduction. Additionally, transcriptional regulation of maternal genes including ASTL has been shown to be critical for successful fertilization and zygotic genome activation, with TCF12-mediated expression patterns in mouse oocytes being prerequisite for proper developmental progression. The propeptide domain of ovastacin, which Triple Point Biologics has targeted in its four rabbit polyclonal clones, represents a functionally important region involved in maintaining enzymatic latency prior to cortical granule release. Understanding ovastacin function has implications beyond basic reproductive biology, including potential applications in assisted reproductive technologies and the investigation of unexplained infertility cases where fertilization failure occurs despite normal gamete parameters.

References

  1. Xie S et al (2025) Novel homozygous variants in ASTL and WEE2 responsible for female infertility characterized by abnormal fertilization. J Assist Reprod Genet. PubMed · DOI
  2. Cao LR et al (2026) Transcription Factor TCF12-Mediated Maternal Gene Expressions in Mouse Oocyte Are Prerequisites of Successful Fertilisation and Zygotic Genome Activation. Cell Prolif. PubMed · DOI

Additional Specifications

Gene Symbol ASTL
UniProt ID Q6HA08
Host Species Rabbit
Species Reactivity Validated- Human
Potential-Mouse, Rat, Pan, Dog
Pack Size 100ug
Immunogen (Propeptide domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 24-63.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 85-282.
Immunogen (Carboxy end Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 242-282.
Immunogen (Carboxyterminal end)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 381-431.
Alternate Names ASTL, Astacin-like metalloendopeptidase, Oocyte astacin, Ovastacin, ZP2-proteinase, EC 3.4.-.-

Frequently Asked Questions

What molecular weight should I expect for ovastacin on a Western blot?

Ovastacin (ASTL) has a predicted molecular weight of approximately 48 kDa based on its 431-residue sequence. However, the observed band may migrate higher due to N-glycosylation, which is common for secreted metalloproteases. In oocyte lysates you may detect the pro-enzyme form, while post-fertilization samples could show processed mature enzyme or cleavage fragments if activation has occurred. Run a positive control lysate from human oocyte-containing tissue alongside your samples, and consider using a reducing gel to resolve disulfide-linked complexes if you see unexpected high-molecular-weight species.

Is this ovastacin antibody validated for immunofluorescence on oocytes?

Triple Point Biologics antibodies are routinely validated for Western blot and immunohistochemistry; immunofluorescence performance depends on epitope accessibility after fixation. For ovastacin IF, start with methanol fixation at minus 20 degrees Celsius or brief paraformaldehyde followed by permeabilization, since ovastacin localizes to cortical granules in the oocyte cytoplasm. Use a starting dilution around 1 to 500 and titrate. Include unfertilized versus fertilized oocytes as biological controls: ovastacin redistributes to the zona pellucida after cortical granule exocytosis, providing an internal spatial control for specificity.

Will this rabbit polyclonal ovastacin antibody work in mouse oocyte samples?

Mouse ovastacin shares substantial sequence identity with human ASTL, so cross-reactivity is predicted but not yet formally validated in our hands. The catalytic astacin domain is highly conserved across mammals. For mouse samples, start with the recommended 1 to 1000 dilution for Western blot and include a human ovarian or oocyte lysate as a positive control on the same membrane. If you observe a band near 48 kDa in mouse but not in a negative control tissue lacking oocytes, that supports specificity. Rat and other mammalian species are similarly predicted based on homology.

What sample preparation is best for detecting ovastacin by Western blot?

Ovastacin is expressed exclusively in oocytes and stored in cortical granules, so whole ovary lysates will be dilute unless you enrich for oocytes. If working with ovarian tissue, consider cumulus-oocyte complexes or denuded oocytes for concentrated signal. Use a standard RIPA or NP-40 lysis buffer with protease inhibitors; ovastacin is a metalloprotease so EDTA in your buffer will inhibit autocatalytic activity. Load 20 to 50 micrograms total protein per lane. For zona pellucida samples post-fertilization, you may need to solubilize zonae separately to detect cleaved ZP2 and residual ovastacin.

What is the recommended starting dilution for ovastacin Western blot?

We recommend a starting dilution of 1 to 1000 for Western blot, which works well with standard chemiluminescent detection when loading 20 to 50 micrograms of oocyte-enriched lysate. If your sample is whole ovary or low in oocyte content, you may need to increase antibody concentration to 1 to 500 or enrich your starting material. Titrate against your specific lysate; polyclonal antibodies from rabbit typically give robust signal in this range. Use five percent milk or BSA in TBS-T for blocking. Expect clean bands with minimal background given the restricted expression pattern of ovastacin.

What controls should I include when using this ovastacin antibody?

Include a positive control rich in oocytes: human cumulus-oocyte complexes, GV or MII stage oocytes, or ovarian lysate are ideal. Negative controls should lack oocytes entirely, such as liver, spleen, or somatic cell lines, since ASTL expression is oocyte-restricted. For functional studies, compare unfertilized oocytes with fertilized embryos at the two-cell stage; ovastacin is secreted from cortical granules after fertilization, so localization shifts. A no-primary-antibody control will rule out secondary antibody artifacts. If available, an ASTL knockout or knockdown sample provides definitive specificity confirmation.

How should I store the ovastacin antibody and what is its shelf life?

Store the antibody at minus 20 degrees Celsius in single-use aliquots to avoid repeated freeze-thaw cycles, which can reduce titer and increase aggregation. The 100-microgram pack size is suitable for aliquoting into 10 to 20 microliter volumes depending on your typical experiment frequency. Polyclonal rabbit antibodies from Triple Point Biologics remain stable for at least two years under these conditions. If you need working stock for frequent use, keep a small aliquot at four degrees Celsius with 0.02 percent sodium azide for up to one month. Do not store diluted antibody in blocking buffer for more than one week.

Does ovastacin have isoforms or splice variants I should be aware of?

Ovastacin is encoded by a single-copy gene, ASTL, and the primary transcript produces a 431-amino-acid protein. Alternative splicing has not been widely reported for ovastacin in the literature, and the UniProt entry Q6HA08 lists one canonical sequence. However, you may observe post-translational modifications: ovastacin is synthesized as a zymogen with a pro-domain that is likely cleaved upon secretion from cortical granules. The antibody targets a broad epitope range, so it should detect both pro-ovastacin and the mature active form. Glycosylation variants may cause band heterogeneity on Western blot as noted earlier.

Western blot validation for RP-Ovastacin — 4 panels across the domain-specific antibody variants. Each blot below shows the clone that validates a specific domain of the target protein.

Ovastacin: Propeptide domain — WB validation
WB · Panel 1 Ovastacin: Propeptide domain
Ovastacin: Catalytic domain — WB validation
WB · Panel 2 Ovastacin: Catalytic domain
Ovastacin: Carboxy end Catalytic domain — WB validation
WB · Panel 3 Ovastacin: Carboxy end Catalytic domain
Ovastacin: Carboxyterminal end — WB validation
WB · Panel 4 Ovastacin: Carboxyterminal end

Custom validation studies available on request — contact us.

Also known as:

  • ASTL
  • Astacin-like metalloendopeptidase
  • Oocyte astacin
  • Ovastacin
  • ZP2-proteinase
  • EC 3.4.-.-
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →